首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS
【24h】

Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS

机译:富马酸二甲酯促进B和T细胞中的B细胞介导的抗炎细胞因子谱,并抑制MS患者的免疫细胞迁移

获取原文
获取原文并翻译 | 示例
           

摘要

Dimethyl Fumarate (DMF), known for its mechanism of action targeting Nrf2 and related redox homeostasis, is an approved immunotherapy for patients with Multiple Sclerosis (PwMS) in the relapsing form. We assessed how DMF modulates immune cell functions, namely the cytokine profile of co-cultured B and T cells, and the chemokine-mediated migration of immune cells. Following DMF therapy, LT alpha(+), TNF alpha(+) and IFN gamma(+) B cells were reduced while TGF beta and IL10 expression elevated. B cells from DMF-treated patients increased TGF beta and LT alpha expression on T cells, while DMF directly reduced TNF alpha(+) and IFN gamma(+) T cells. CXCL12/CXCL13-mediated migration of B cells, Monocytes, CD4 and CD8 T cells was reduced, with altered CXCR5 and CXCR4 expression. Induction of regulatory B and T cells and reduced migration of immune cells may be part of the beneficial mechanism of DMF in PwMS.
机译:富马酸二甲烷(DMF),其作用机制靶向NRF2和相关氧化还原稳态,是复发形式中多发性硬化症(PWM)患者的批准免疫疗法。 我们评估了DMF如何调节免疫细胞功能,即共培养的B和T细胞的细胞因子谱,以及趋化因子介导的免疫细胞的迁移。 在DMF疗法之后,在TGFβ和IL10表达升高时,降低了DMF疗法,LTα(+),TNFα(+)和IFNγ(+)B细胞。 来自DMF处理的患者的B细胞增加TGFβ并在T细胞上增加α表达,而DMF直接降低TNFα(+)和IFNγ(+)T细胞。 CXCL12 / CXCL13介导的B细胞,单核细胞,CD4和CD8 T细胞的迁移,CXCR5和CXCR4表达改变。 调节性B和T细胞的诱导和免疫细胞的减少迁移可能是PWMS中DMF的有益机制的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号